Epidemiology of Gliomas

Ostrom, Quinn T.; Gittleman, Haley; Stetson, Lindsay; Virk, Selene; Barnholtz‐Sloan, Jill S.

doi:10.1007/978-3-319-12048-5_1

Cited by 352 publications

(269 citation statements)

References 53 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…The most common gliomas are astrocytomas and oligodendrogliomas (Ostrom et al 2015b). The prognosis and treatment are primarily based on the malignancy grade of the tumour, although tumours with an oligodendroglial component generally have a more favourable prognosis than astrocytic tumours (Ostrom et al 2015b). …”

Section: Background Gliomasmentioning

confidence: 99%

Challenges and support for family caregivers of glioma patients

Boele

Grant²,

Sherwood

2017

British Journal of Neuroscience Nursing

View full text Add to dashboard Cite

Glioma patients are not only confronted with the diagnosis and treatment of cancer, but often experience disease-specific symptoms that greatly affect everyday life. Common symptoms among patients include motor dysfunction, sensory loss, seizures, cognitive deficits, changes in behaviour and personality, mood issues, and fatigue. This review focuses on family caregivers, for whom dealing with the diagnosis and treatment of a brain tumour in their loved one while managing disease-specific symptoms can be challenging. Supportive interventions to assist caregivers have been reported, but high quality scientific evidence for the effectiveness of these programs is largely lacking. Further research is needed to determine how we can best support family caregivers to manage glioma patients' symptoms while maintaining their own health as a caregiver. Research is also required in evaluating the health economic benefits of support programs for caregivers, as better care for caregivers may potentially reduce overall healthcare costs. KeywordsFamily caregiving; informal caregiving; glioma; brain tumour; supportive care Key points-Psychological distress is reported in approximately half of family caregivers in neuro-oncology; -Providing assistance for family caregivers may prevent them from developing emotional or physical problems themselves; -Research shows that family caregivers of glioma patients can benefit from information and concrete advice on dealing with everyday difficulties; -More research is needed as large-scale implementation of caregiver support may be hindered by the lack of high quality scientific evidence for the beneficial effects of caregiver interventions in neuro-oncology.

show abstract

Section: Background Gliomasmentioning

confidence: 99%

Challenges and support for family caregivers of glioma patients

Boele

Grant²,

Sherwood

2017

British Journal of Neuroscience Nursing

View full text Add to dashboard Cite

show abstract

“…4 Glioblastoma (GBM) is the most common primary malignant central nervous system (CNS) tumor in adults, accounting for »54% of all malignant glioma diagnoses. 5,6 Despite the current standard of care regimen including maximum surgical resection, radiotherapy (RT) and chemotherapy, median overall survival (OS) remains at 14.6 mo with less than 26% of patients surviving at 2 y postdiagnosis. [7][8][9] In the absence of therapy, OS is limited to 30-35 weeks.…”

Section: Malignant Gliomamentioning

confidence: 99%

Improving vaccine efficacy against malignant glioma

et al. 2016

View full text Add to dashboard Cite

The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Ra2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

show abstract

“…In 2015, about 23,189 new primary malignant brain tumors will be diagnosed in the United States with 13,330 predicted deaths [1][2][3]. Gliomas, the most common malignant primary tumor of the central nervous system (CNS), present with an annual incidence of about 5 in 100,000 with glioblastoma (GBM), the most common and aggressive subtype constituting 54 % of gliomas [2,3].…”

Section: Introductionmentioning

confidence: 99%

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

Neagu

Reardon

2015

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Existing therapies for glioblastoma (GBM), the most common malignant primary brain tumor in adults, have fallen short of improving the dismal patient outcomes, with an average 14-16-month median overall survival. The biological complexity and adaptability of GBM, redundancy of dysregulated signaling pathways, and poor penetration of therapies through the blood-brain barrier contribute to poor therapeutic progress. The current standard of care for newly diagnosed GBM consists of maximal safe resection, followed by fractionated radiotherapy combined with concurrent temozolomide (TMZ) and 6-12 cycles of adjuvant TMZ. At progression, bevacizumab with or without additional chemotherapy is an option for salvage therapy. The recent FDA approval of sipuleucel-T for prostate cancer and ipilumimab, nivolumab, and pembrolizumab for select solid tumors and the ongoing trials showing clinical efficacy and response durability herald a new era of cancer treatment with the potential to change standard-of-care treatment across multiple cancers. The evaluation of various immunotherapeutics is advancing for GBM, putting into question the dogma of the CNS as an immuno-privileged site. While the field is yet young, both active immunotherapy involving vaccine strategies and cellular therapy as well as reversal of GBM-induced global immune-suppression through immune checkpoint blockade are showing promising results and revealing essential immunological insights regarding kinetics of the immune response, immune evasion, and correlative biomarkers. The future holds exciting promise in establishing new treatment options for GBM that harness the patients' own immune system by activating it with immune checkpoint inhibitors, providing specificity using vaccine therapy, and allowing for modulation and enhancement by combinatorial approaches.

show abstract

Epidemiology of Gliomas

Cited by 352 publications

References 53 publications

Challenges and support for family caregivers of glioma patients

Challenges and support for family caregivers of glioma patients

Improving vaccine efficacy against malignant glioma

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

Contact Info

Product

Resources

About